Autolus Therapeutics (AUTL) said late Friday its Aucatzyl programmed T cell therapy has received marketing authorization from the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The safety of Aucatzyl includes a boxed warning for cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies, the company said.

Autolus said it is planning to produce the new medication at its manufacturing facility in the UK.

Shares of the company were up 1.9% in after-hours activity.

Price: 3.8001, Change: +0.07, Percent Change: +1.88